Cargando…

Rationale for Stereotactic Body Radiation Therapy in Treating Patients with Oligometastatic Hormone-Naïve Prostate Cancer

Despite advances in treatment for metastatic prostate cancer, patients eventually progress to castrate-resistant disease and ultimately succumb to their cancer. Androgen deprivation therapy (ADT) is the standard treatment for metastatic prostate cancer and has been shown to improve median time to pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhattasali, Onita, Chen, Leonard N., Tong, Michael, Lei, Siyuan, Collins, Brian T., Krishnan, Pranay, Kalhorn, Christopher, Lynch, John H., Suy, Simeng, Dritschilo, Anatoly, Dawson, Nancy A., Collins, Sean P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2013
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3847811/ https://www.ncbi.nlm.nih.gov/pubmed/24350058 http://dx.doi.org/10.3389/fonc.2013.00293

Ejemplares similares

Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer
por: Bhattasali, Onita, et al.
Publicado: (2014)

Stereotactic Body Radiation Therapy for Prostate Cancer: What is the Appropriate Patient-Reported Outcome for Clinical Trial Design?
por: Woo, Jennifer Ai-Lian, et al.
Publicado: (2015)

Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3))
por: Janowski, Einsley, et al.
Publicado: (2014)

Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer
por: Gurka, Marie K, et al.
Publicado: (2015)

Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose Reduction
por: Repka, Michael C., et al.
Publicado: (2016)

Proctitis 1 Week after Stereotactic Body Radiation Therapy for Prostate Cancer: Implications for Clinical Trial Design
por: Paydar, Ima, et al.
Publicado: (2016)

Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Janowski, Einsley-Marie, et al.
Publicado: (2015)

Improved Irritative Voiding Symptoms 3 Years after Stereotactic Body Radiation Therapy for Prostate Cancer
por: Rana, Zaker, et al.
Publicado: (2014)

Rectal endoscopy findings following stereotactic body radiation therapy for clinically localized prostate cancer
por: Sood, Sumit, et al.
Publicado: (2013)

Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer
por: Arscott, W Tristram, et al.
Publicado: (2014)

Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience
por: Chen, Leonard N, et al.
Publicado: (2013)

Urethrogram-Directed Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer in Patients with Contraindications to Magnetic Resonance Imaging
por: Paydar, Ima, et al.
Publicado: (2015)

Clinical Characteristics and Management of Late Urinary Symptom Flare Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Woo, Jennifer A., et al.
Publicado: (2014)

Proctitis following stereotactic body radiation therapy for prostate cancer
por: Joh, Daniel Y, et al.
Publicado: (2014)

Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer
por: Chen, Leonard N, et al.
Publicado: (2014)

Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation Therapy
por: Carrasquilla, Michael, et al.
Publicado: (2021)

Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: The Georgetown University Experience
por: Mercado, Catherine, et al.
Publicado: (2016)

Potency preservation following stereotactic body radiation therapy for prostate cancer
por: Obayomi-Davies, Olusola, et al.
Publicado: (2013)

Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer
por: Ju, Andrew W, et al.
Publicado: (2013)

Long-Term Outcomes Following Conventionally Fractionated Stereotactic Boost for High-Grade Gliomas in Close Proximity to Critical Organs at Risk
por: Repka, Michael C., et al.
Publicado: (2018)

Six-Dimensional Correction of Intra-Fractional Prostate Motion with CyberKnife Stereotactic Body Radiation Therapy
por: Lei, Siyuan, et al.
Publicado: (2011)

Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity
por: Paydar, Ima, et al.
Publicado: (2017)

Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP)
por: Pepin, Abigail, et al.
Publicado: (2020)

Management of Isolated Local Failures Following Stereotactic Body Radiation Therapy for Low to Intermediate Risk Prostate Cancer
por: Aghdam, Nima, et al.
Publicado: (2020)

Utilization of Patient-Reported Outcomes to Guide Symptom Management during Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer
por: Danner, Malika, et al.
Publicado: (2017)

Self-Reported Burden in Elderly Patients With Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT)
por: Aghdam, Nima, et al.
Publicado: (2020)

Impact of Age on Patient-Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Pepin, Abigail, et al.
Publicado: (2021)

Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure?
por: Kataria, Shaan, et al.
Publicado: (2017)

Fiducial-free CyberKnife stereotactic body radiation therapy (SBRT) for single vertebral body metastases: acceptable local control and normal tissue tolerance with 5 fraction approach
por: Gill, Beant, et al.
Publicado: (2012)

Scoring system predictive of survival for patients undergoing stereotactic body radiation therapy for liver tumors
por: Kress, Marie-Adele S, et al.
Publicado: (2012)

Bleeding Risk Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer in Men on Baseline Anticoagulant or Antiplatelet Therapy
por: Pepin, Abigail, et al.
Publicado: (2021)

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS ≥ 15)
por: Aghdam, Nima, et al.
Publicado: (2020)

Stereotactic Body Radiation Therapy for Liver Metastases from Colorectal Cancer: Analysis of Safety, Feasibility, and Early Outcomes
por: Kress, Marie-Adele S., et al.
Publicado: (2012)

Testosterone as a Biomarker for Quality of Life (QOL) Following Androgen Deprivation Therapy (ADT) and Stereotactic Body Radiotherapy (SBRT)
por: Shah, Sarthak, et al.
Publicado: (2023)

Treatment Interruptions During Stereotactic Body Radiotherapy for Prostate Cancer
por: Pepin, Abigail N., et al.
Publicado: (2022)

The Impact of Obesity on Patient Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Koneru, Harsha, et al.
Publicado: (2016)

CyberKnife for hilar lung tumors: report of clinical response and toxicity
por: Unger, Keith, et al.
Publicado: (2010)

Bothersome Hematospermia Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Shah, Sarthak, et al.
Publicado: (2021)

Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer
por: Oermann, Eric K, et al.
Publicado: (2011)

Stereotactic Ablative Radiotherapy for Oligometastatic Disease in Liver
por: Kim, Myungsoo, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0f02hfh9ei8tletuqupg24r2hl